ASCO 2021 | Future directions in melanoma

James Larkin, PhD, FRCP, The Royal Marsden NHS Foundation Trust, London, UK, discusses what to expect in melanoma at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting, including results from the Phase III RELATIVITY-047 trial (NCT03470922) of nivolumab and the anti-LAG-3 relatlimab in patients with advanced melanoma. Dr Larkin additionally shares his expectations in selecting patients for specific treatments based on the tumor characteristics, as well as novel cellular therapies for patients with melanoma. This interview took place at the ASCO 2021 Virtual Meeting.